Ortivus (ORTI) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 decreased by 18% year-over-year to SEK 18.1 million, with ongoing contracts contributing SEK 9.3 million.

• Gross margin improved to 42% from 41% despite lower sales, reflecting efficiency measures.

• EBITDA was SEK -1.1 million, slightly worse than SEK -1.0 million in Q1 2024.

• Net profit after tax was SEK -2.5 million, compared to SEK -2.2 million a year earlier.

• Cash flow from operating activities improved to SEK -4.8 million from SEK -6.4 million.

Financial highlights

• Operating profit for Q1 2025 was SEK -2.5 million, down from SEK -2.0 million in Q1 2024.

• Operating margin declined to -14% from -9% year-over-year.

• Cash and cash equivalents at period end were SEK 2.1 million, up from SEK 1.3 million in Q1 2024.

• Investments in intangible and tangible assets reached SEK 3.3 million during the quarter.

• Market capitalization at period end was SEK 74.7 million, down from SEK 134.4 million a year earlier.

Outlook and guidance

• Continued focus on platform-independent technology, iOS, and cloud-based services to meet healthcare digitalization needs.

• Ongoing investments in innovation and team development to support sustainable growth.

• No formal forecasts provided; forward-looking statements subject to risks and uncertainties.